The Retinal Pigment Epithelial Detachment changes in Aged-related macular degeneration treated with Aflibercept, Ranibizumab and Bevacizumab

Phase 4

Recruiting

• Conditions: wet AMDRPED; RPED; Retinal Pigment Epithelial Detachment; AMD; Age- related Macular Degeneration; Anti- VEGF; Vascular endothelial growth factor; Aflibercept

• Registration Number: TCTR20161007004
• Lead Sponsor: Faculty of Medicine, Chulalongkorn University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10-07
• Study Completion: 2017-10-10
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1.Newly diagnosed wet AMD patient confirmed by FFA or OCT and diagnosed by retina specialist in 2010 to 2017
2.Presence of PED at the time of diagnosis
3.No history of previous macular laser treatment or photodynamic therapy
4.No concurrent other macular diseases in the study eye
Obtained OCT scanning from SPECTRALIS SD-OCT

Exclusion Criteria

1.Poor quality of OCT image at baseline and at 12th month visit
2.Lost follow up before 6th month visit
3.Presence of RPE rip after initial Anti VEGF treatment

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Height and area of Pigment epithelial detachment 6 months Optical coherence tomography

Secondary Outcome Measures

Name	Time	Method
Visual acuity 6 months ETDRS chart,Sub retinal fluid 6 months Optical coherence tomography,Central foveal thickness 6months Optical coherence tomography,Number of injections and visits 6months From chart review